Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Ugbena, Richard ^a   Aberle Grasse, John ^b   Diallo, Karidia ^b   Bassey, Orji ^a   Jelpe, Tapdiyel ^a   Rottinghaus, Erin ^b   Azeez, Aderemi ^c   Akpan, Raphael ^a   Muhammad, Mukhtar ^a   Shanmugam, Vedapuri ^b   Singh, Satvinder ^a   Yang, Chunfu ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Ministry of Federal Health Nigeria   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NIGERIA; PILOT STUDY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; MALE; NIGERIA; TREATMENT OUTCOME; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84860358499     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir1064     Document Type: Review

References (22)

1. National AIDS/STDs Control Program, Federal Ministry of Health. 2007/2008 HIV/STI integrated biological and behavioral surveillance survey. Abuja, Nigeria: Federal Ministry of Health, 2008.
2. National AIDS/STDs Control Program, Federal Ministry of Health. 2007 National guideline for HIV and AIDS treatment and care in adolescents and adults. Abuja, Nigeria: Federal Ministry of Health, 2007.
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 revision. Geneva, Switzerland: World Health Organization Press, 2010.
4. Walensky RP, Wood R, Ciaranello AL, et al. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med 2010; 7:e1000382.
5. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-9.
6. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)
7. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
8. Yang C, McNulty A, Diallo K, et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 2010; 48: 3158-64.
9. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18.
10. Abegaz WE, Grossman Z, Wolday D, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir Ther 2008; 13(Suppl 2):89-94. (Pubitemid 352019094)
11. Hammer SM, Eron JJ Jr, Reiss P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-70.
12. Barth RE, van der LoeffMF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
13. Ojesina AI, Sankale JL, Odaibo G, et al. Subtype-specific patterns in HIV type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response. AIDS Res Hum Retroviruses 2006; 22:770-9. (Pubitemid 44735004)
14. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8. (Pubitemid 30261205)
15. Hawkins CA, Chaplin B, Idoko J, et al. APIN Plus/Harvard PEPFAR Team. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. J Acquir Immune Defic Syndr 2009; 52:228-34.
16. Brenner B, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 2009; 3:583-94.
17. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23: 1127-34.
18. Wallis CL, Mellors JW, VenterWD, Sanne I, StevensW. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-4.
19. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009; 151: 241-51, W-52.
20. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resourcelimited settings. Curr Opin HIV AIDS 2010; 5:18-26.
21. Gupta R, Pillay D, Ranopa M, et al. DART Virology Group. Rapid accumulation of thymidine-analog mutations and virologic implications in the absence of viral load monitoring [paper 618]. In: 18th Conference on Retroviruses and Opportunistic Infections. Alexandria, Virginia: CROI, 2011: 310.
22. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-71. (Pubitemid 46684328)